Osteopontin promotes oncostatin M production in human osteoblasts: Implication of rheumatoid arthritis therapy

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3355-3364

  Su, Chen Ming ^a,b   Chiang, Yi Chun ^b   Huang, Chun Yin ^b,c   Hsu, Chin Jung ^d,e   Fong, Yi Chin ^d,e   Tang, Chih Hsin ^b,f,g  

^a AFFILIATED DONGYANG HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOSTATIN M; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN C JUN; PROTEIN KINASE P60; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR AP 1; VITRONECTIN RECEPTOR; OSM PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BINDING; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE EROSION; CARTILAGE INJURY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; JOINT SWELLING; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; TRANSACTIVATION; ANIMAL; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; EXPERIMENTAL ARTHRITIS; GENETICS; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; INTEGRIN ALPHAVBETA3; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; ONCOSTATIN M; OSTEOBLASTS; OSTEOPONTIN; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84942455878     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403191     Document Type: Article

References (51)

1. Bartok, B., and G. S. Firestein. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233: 233-255.
2. Grabiec, A. M., O. Korchynskyi, P. P. Tak, and K. A. Reedquist. 2012. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71: 424-431.
3. Bellido, T., N. Stahl, T. J. Farruggella, V. Borba, G. D. Yancopoulos, and S. C. Manolagas. 1996. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J. Clin. Invest. 97: 431-437.
4. Sims, N. A., and J. M. Quinn. 2014. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. Bonekey Rep. 3: 527.
5. Wahl, A. F., and P. M. Wallace. 2001. Oncostatin M in the anti-inflammatory response. Ann. Rheum. Dis. 60(Suppl. 3): iii75-iii80.
6. Staines, K. A., V. E. MacRae, and C. Farquharson. 2012. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J. Endocrinol. 214: 241-255.
7. Wai, P. Y., and P. C. Kuo. 2008. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 27: 103-118.
8. Chabas, D., S. E. Baranzini, D. Mitchell, C. C. Bernard, S. R. Rittling, D. T. Denhardt, R. A. Sobel, C. Lock, M. Karpuj, R. Pedotti, et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735.
9. Zheng, W., R. Li, H. Pan, D. He, R. Xu, T. B. Guo, Y. Guo, and J. Z. Zhang. 2009. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1b through the NF-kB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum. 60: 1957-1965.
10. Gravallese, E. M. 2003. Osteopontin: a bridge between bone and the immune system. J. Clin. Invest. 112: 147-149.
11. Xu, G., H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, and J. Z. Zhang. 2005. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115: 1060-1067.
12. Petrow, P. K., K. M. Hummel, J. Schedel, J. K. Franz, C. L. Klein, U. Müller-Ladner, J. Kriegsmann, P. L. Chang, C. W. Prince, R. E. Gay, and S. Gay. 2000. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 43: 1597-1605.
13. Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, and M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561.
14. Wang, K. X., and D. T. Denhardt. 2008. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19: 333-345.
15. Lisignoli, G., A. Piacentini, S. Toneguzzi, F. Grassi, B. Cocchini, A. Ferruzzi, G. Gualtieri, and A. Facchini. 2000. Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M. Clin. Exp. Immunol. 119: 346-353.
16. Huang, C. Y., S. Y. Chen, H. C. Tsai, H. C. Hsu, and C. H. Tang. 2012. Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. Arthritis Rheum. 64: 3344-3354.
17. Su, C. M., S. W. Wang, T. H. Lee, W. P. Tzeng, C. J. Hsiao, S. C. Liu, and C. H. Tang. 2013. Trichodermin induces cell apoptosis through mitochondrial dysfunction and endoplasmic reticulum stress in human chondrosarcoma cells. Toxicol. Appl. Pharmacol. 272: 335-344.
18. Tzeng, H. E., C. H. Tsai, Z. L. Chang, C. M. Su, S. W. Wang, W. L. Hwang, and C. H. Tang. 2013. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem. Pharmacol. 85: 531-540.
19. Ma, Y., R. J. Streiff, J. Liu, M. J. Spence, and R. E. Vestal. 1999. Cloning and characterization of human oncostatin M promoter. Nucleic Acids Res. 27: 4649-4657.
20. Bäcklund, J., C. Li, E. Jansson, S. Carlsen, P. Merky, K. S. Nandakumar, S. Haag, J. Ytterberg, R. A. Zubarev, and R. Holmdahl. 2013. C57BL/6 mice need MHC class II Aq to develop collagen-induced arthritis dependent on autoreactive T cells. Ann. Rheum. Dis. 72: 1225-1232.
21. Su, C. M., C. J. Hsu, C. H. Tsai, C. Y. Huang, S. W. Wang, and C. H. Tang. 2015. Resistin promotes angiogenesis in endothelial progenitor cells through inhibition of MicroRNA206: potential implications for rheumatoid arthritis. Stem Cells 33: 2243-2255.
22. Take, Y., K. Nakata, J. Hashimoto, H. Tsuboi, N. Nishimoto, T. Ochi, and H. Yoshikawa. 2009. Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6. Arthritis Rheum. 60: 3591-3601.
23. Baum, R., and E. M. Gravallese. 2014. Impact of inflammation on the osteoblast in rheumatic diseases. Curr. Osteoporos. Rep. 12: 9-16.
24. Hintzen, C., S. Quaiser, T. Pap, P. C. Heinrich, and H. M. Hermanns. 2009. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum. 60: 1932-1943.
25. Guihard, P., Y. Danger, B. Brounais, E. David, R. Brion, J. Delecrin, C. D. Richards, S. Chevalier, F. Rédini, D. Heymann, et al. 2012. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 30: 762-772.
26. Nakamura, I., T. Duong, S. B. Rodan, and G. A. Rodan. 2007. Involvement of avb3 integrins in osteoclast function. J. Bone Miner. Metab. 25: 337-344.
27. Glinskii, O. V., F. Li, L. S. Wilson, S. Barnes, K. Rittenhouse-Olson, J. J. Barchi, Jr., K. J. Pienta, and V. V. Glinsky. 2014. Endothelial integrin a3b1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane. Oncotarget 5: 1382-1389.
28. Gonfloni, S., A. Weijland, J. Kretzschmar, and G. Superti-Furga. 2000. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 7: 281-286.
29. Hsieh, H. L., H. H. Wang, C. Y. Wu, W. H. Tung, and C. M. Yang. 2010. Lipoteichoic acid induces matrix metalloproteinase-9 expression via transactivation of PDGF receptors and NF-kB activation in rat brain astrocytes. Neurotox. Res. 17: 344-359.
30. Nemoto, E., M. Shimonishi, Y. Nitta, and H. Shimauchi. 2004. The involvement of platelet-derived growth factor receptors and insulin-like growth factor-I receptors signaling during mineralized nodule formation by human periodontal ligament cells. J. Periodontal Res. 39: 388-397.
31. Chan, C. M., H. H. Chang, V. C. Wang, C. L. Huang, and C. F. Hung. 2013. Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRb, PI3K/Akt and MAPK pathways. PLoS One 8: e56819.
32. Schonthaler, H. B., J. Guinea-Viniegra, and E. F. Wagner. 2011. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann. Rheum. Dis. 70(Suppl. 1): i109-i112.
33. Kastl, S. P., W. S. Speidl, C. Kaun, K. M. Katsaros, G. Rega, T. Afonyushkin, V. N. Bochkov, P. Valent, A. Assadian, G. W. Hagmueller, et al. 2008. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler. Thromb. Vasc. Biol. 28: 498-503.
34. Herenius, M. M., R. M. Thurlings, C. A. Wijbrandts, R. J. Bennink, S. E. Dohmen, C. Voermans, D. Wouters, E. S. Izmailova, D. M. Gerlag, B. L. van Eck-Smit, and P. P. Tak. 2011. Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab. Ann. Rheum. Dis. 70: 1160-1162.
35. Matzelle, M. M., M. A. Gallant, K. W. Condon, N. C. Walsh, C. A. Manning, G. S. Stein, J. B. Lian, D. B. Burr, and E. M. Gravallese. 2012. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 64: 1540-1550.
36. Walsh, N. C., and E. M. Gravallese. 2010. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 233: 301-312.
37. Yokosaki, Y., N. Matsuura, T. Sasaki, I. Murakami, H. Schneider, S. Higashiyama, Y. Saitoh, M. Yamakido, Y. Taooka, and D. Sheppard. 1999. The integrin a9b1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J. Biol. Chem. 274: 36328-36334.
38. Boumans, M. J., J. G. Houbiers, P. Verschueren, H. Ishikura, R. Westhovens, E. Brouwer, B. Rojkovich, S. Kelly, M. den Adel, J. Isaacs, et al. 2012. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann. Rheum. Dis. 71: 180-185.
39. Rodan, G. A. 1995. Osteopontin overview. Ann. N. Y. Acad. Sci. 760: 1-5.
40. Morimoto, J., S. Kon, Y. Matsui, and T. Uede. 2010. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr. Drug Targets 11: 494-505.
41. Chen, G., X. Zhang, R. Li, L. Fang, X. Niu, Y. Zheng, D. He, R. Xu, and J. Z. Zhang. 2010. Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum. 62: 2900-2908.
42. Chen, Y. J., Y. Y. Wei, H. T. Chen, Y. C. Fong, C. J. Hsu, C. H. Tsai, H. C. Hsu, S. H. Liu, and C. H. Tang. 2009. Osteopontin increases migration and MMP-9 up-regulation via avbb3 integrin, FAK, ERK, and NF-kB-dependent pathway in human chondrosarcoma cells. J. Cell. Physiol. 221: 98-108.
43. Plater-Zyberk, C., J. Buckton, S. Thompson, J. Spaull, E. Zanders, J. Papworth, and P. F. Life. 2001. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum. 44: 2697-2702.
44. Ramaiah, S. K., and S. Rittling. 2008. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 103: 4-13.
45. Lund, S. A., C. L. Wilson, E. W. Raines, J. Tang, C. M. Giachelli, and M. Scatena. 2013. Osteopontin mediates macrophage chemotaxis via a4 and a9 integrins and survival via the a4 integrin. J. Cell. Biochem. 114: 1194-1202.
46. Wilder, R. L. 2002. Integrin aVb3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61(Suppl. 2): ii96-ii99.
47. Yamamoto, N., F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, and T. Uede. 2003. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Invest. 112: 181-188.
48. Caverzasio, J., E. Biver, and C. Thouverey. 2013. Predominant role of PDGF receptor transactivation in Wnt3a-induced osteoblastic cell proliferation. J. Bone Miner. Res. 28: 260-270.
49. Kastl, S. P., W. S. Speidl, K. M. Katsaros, C. Kaun, G. Rega, A. Assadian, G.W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, et al. 2009. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 114: 2812-2818.
50. Felson, D. 2012. Defining remission in rheumatoid arthritis. Ann. Rheum. Dis. 71(Suppl. 2): i86-i88.
51. Brand, D. D., A. H. Kang, and E. F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18.